Surrozen Q3 net loss $71.6M, appoints new CFO

Surrozen, Inc./DE

2025-Q3 EPS reported -$8.49 revenue$2,949,000

Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.
Revenue fell to $1.0M (all from related party) from $10.0M in Q3 2024, due to absence of Boehringer Ingelheim milestone payment.
Cash $81.3M at Sep 30, 2025 (down from $90.4M at Jun 30); R&D $7.8M vs $5.2M, G&A $4.1M vs $3.6M YoY.
Andrew Maleki appointed CFO effective Nov 12, 2025; Charles Williams continues as COO and Secretary.
Company on track to submit IND for SZN-8141 in 2026; ophthalmology pipeline remains focus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.